Sars-Cov-1 Neutralizing Antibody Test Cost
Lab Reagents
Human IgG antibody Laboratories manufactures the sars-cov-1 neutralizing antibody test cost reagents distributed by Genprice. The Sars-Cov-1 Neutralizing Antibody Test Cost reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Sars-Cov-1 products are available in stock. Specificity: Sars-Cov-1 Category: Neutralizing Group: Antibody Test
SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag |
|||
E80022 | EpiGentek |
|
|
SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag |
|||
E80025 | EpiGentek |
|
|
3CL Protease (SARS-CoV-2) |
|||
100823-1 | BPS Bioscience | 50 µg | EUR 400 |
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), expressed in an E. coli expression system, MW=34 kDa. |
Spike (SARS-CoV-2) Lentivirus |
|||
78010-1 | BPS Bioscience | 100 µl | EUR 835 |
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_ |
Anti-Spike S1 Antibody (SARS-CoV-2) |
|||
100715-1 | BPS Bioscience | 20 µg | EUR 300 |
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus. |
3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate |
|||
79952-2 | BPS Bioscience | 10 mg | EUR 3460 |
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹. |
PLPro, His-tag (1541-1857) (SARS-CoV-1) |
|||
100903-1 | BPS Bioscience | 100 µg | EUR 335 |
Description: Severe acute respiratory Coronavirus 1 Papain-Like Protease (PLPro), also known as PLP and NSP3, GenBank Accession No. NP_828862.2, a.a. 1541-1857 with N-terminal His-tag, expressed in an E. coli expression system, MW=37 kDa. |
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter) |
|||
78614-1 | BPS Bioscience | 100 µl | EUR 860 |
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951). |
PLPro, His-tag (SARS-CoV-2) |
|||
100735-1 | BPS Bioscience | 100 µg | EUR 350 |
Description: SARS-Cov-2 papain-like protease (PLPro), part of a large replicase polyprotein 1ab (E1564-Y1882), GenBank Accession No. QHD43415, with a N-terminal His-tag, expressed in an E. coli expression system. MW=38 kDa. |
NSP10/NSP16 Complex (SARS-CoV-2) |
|||
100747-1 | BPS Bioscience | 100 µg | EUR 320 |
Description: Complex of SARS-CoV-2 nonstructural protein 10 (NSP10), GenBank Accession No. YP_009725306.1, a.a. 1-139(full length), with N-terminal FLAG-tag, MW=16 kDa and SARS-CoV-2 nonstructural protein 16 (NSP16), Genbank Accession No. YP_009725311, a.a. 1-298(full length), with N-terminal His-tag, MW=34 kDa, co-expressed in a HEK293 cell expression system. |
NSP7, His-tag (SARS-CoV-2) |
|||
100829-1 | BPS Bioscience | 100 µg | EUR 320 |
Description: SARS-CoV-2 nonstructural protein 7 (NSP7), Genbank Accession No.: YP_009742614, a.a. 1-84(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 10 kDa. |
NSP8, His-tag (SARS-CoV-2) |
|||
100830-1 | BPS Bioscience | 100 µg | EUR 335 |
Description: SARS-CoV-2 nonstructural protein 8 (NSP8), Genbank Accession No.: YP 009725304.1, a.a. 1-198(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 23 kDa. |
ORF9b, GST-Tag (SARS-CoV-2) |
|||
100962-1 | BPS Bioscience | 100 µg | EUR 320 |
Description: Recombinant ORF9b, full length, encompassing amino acids 1-97(end). This recombinant protein corresponds to SARS-CoV-2 accessory protein ORF9b. It was expressed in E.coli and contains an N-terminal GST tag and a prescission protease cleavage site. The recombinant protein is >90% pure following GST affinity purification. |
Spike S1 Neutralizing Antibody (VHH), Fc-fusion (IgG1), Avi-Tag (SARS-CoV) |
|||
100784 | BPS Bioscience | 100 µg | EUR 595 |
Description: SARS-CoV monoclonal Spike S1 VHH neutralizing antibody, a.a. 1-127(full length), with C-terminal Avi-Tag™ fused to the Fc portion of Human IgG1, expressed in a HEK293 cell expression system. MW = 43 kDa. VHHs are single-domain antibodies from camelids. |
Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) |
|||
IOV87952 | INVBIO | 20T/kit | EUR 46.8 |
Description: Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid immunochromatographic method. The identification is based on the monoclonal antibodies specific for the novel coronvirus antigen. It will provide information for clinical doctors to prescribe correct medications. |
SARS-CoV Spike Antibody |
|||
3219-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3219-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |